Related to Celera Gets CE Mark for KIF6 Genetic Test for Coronary Heart Disease Risk

• Merck & Co. Buys Rights to Atrial Fibrillation Therapy from Cardiome for $60M Up Front
  
• Prometheus Gains U.S. Rights to Rosetta's Cancer Tests
  
• LDL-Controlling Protein Exerts Effect Extracellularly
  
• Sequenom Reduces Workforce in Genetic Analysis Unit
  
• Epigenomics Grants Predictive Biosciences Rights to Use a Biomarker in a Prostate Cancer Test
  
• Role of COMT Gene Mutation in Post Heart Surgery Complications Revealed
  
• Genetic Profile Found that Predicts Best Chemotherapy for Ovarian Cancers
  
• Alethia Licenses Preclinical Cancer mAbs for Drug and Diagnostic Development
  
• Diatherix Releases Swine Flu Virus Test
  
• The Medicines Company Axes Phase III Percutaneous Coronary Intervention Program
  
• Roche Launches Swine Flu Detection Kit for Research Purposes
  
• Collaboration Formed to Evaluate Epigenomics’ Test in Detecting Colorectal Polyps
  
• Amgen Obtains Cardiovascular Program for $50M from Cytokinetics
  
• Blanchette Rockefeller Neurosciences Institute and Inverness Join Forces for Alzheimer's Diagnostic
  
• ExonHit Licenses IP for Breast Cancer Test from Institut Gustave Roussy
  
• Novartis' Osteoporosis Drug Gets FDA Okay for Preventing Postmenopausal Osteoporosis
  
• Takeda Pulls MAA for Type 2 Diabetes Therapy
  
• Roche, SeqWright, and Miller School of Medicine in Search of Genetic Causes of Dilated Cardiomyopathy
  
• Interleukin Genetics Introduces Weight Management Genetic Test
  
• NHLBI and UnitedHealth Join Forces to Create Research Centers for Chronic Diseases in Developing Countries